Delivery Order SPE2DB24D9224-SPE2DB24FJGEK

Award Date 7/23/24
Potential Completion Date 7/24/24
Potential Value $4.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,169.59 firm fixed-price delivery order is for the supply of 120 tablets of the pharmaceutical product Xtandi 40 mg. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the agency to...
This award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order under the Defense Logistics Agency's (DLA) SPE2DB indefinite delivery contract (IDC) valued at up to $499,999,999. The IDC allows the DLA to issue delivery orders for a comprehensive range of pharmaceutical items, including common and specialized medications, to support the recurring medical supply needs of Department of Defense (DoD) healthcare facilities worldwide. This particular...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,508.77 firm fixed-price delivery order is for the supply of 120 units of the prescription medication Xtandi 40 mg tablets. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA), which is part of the U.S. Department of Defense (DoD), to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract has a ceiling value of $51,736.20 and is a firm fixed-price delivery order for the supply of the pharmaceutical product Xtandi 40 mg capsule, with a completion date of August 9, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $4,311.35, is a firm fixed-price delivery order for the supply of Xtandi 40 mg capsules. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order under the Defense Logistics Agency's (DLA) SPE2DB medical supply contract vehicle. The contract, valued at $4,169.59, is for the supply of the drug Xtandi 80 mg tablets to support the recurring pharmaceutical needs of the U.S. Department of Defense (DoD) healthcare facilities worldwide. DMS Pharmaceutical Group is a key supplier of a wide range of pharmaceutical...
The U.S. Defense Logistics Agency (DLA) awarded a $25,929 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) with DLA under the SPE2DB program, which covers a wide range of pharmaceutical products to support the medical supply needs of military health facilities worldwide. This order is for Xtandi 40 mg capsules and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,339.18 firm fixed-price delivery order is for the supply of 120 units of the prescription drug Xtandi 40 mg tablets. The contract has an ultimate completion date of December 16, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $4,169.59 firm fixed-price delivery order contract provides Xtandi 40 mg tablets to support the recurring medical supply needs of military health facilities. The contract is part of DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $4,169.59 firm fixed-price delivery order is for the supply of the prescription drug Xtandi (40 mg tablets) to support the medical needs of military personnel and their dependents at Department of Defense (DoD) healthcare facilities. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite...
  • SPE2DB24D9224
    Indefinite Delivery Contract
  • SPE2DB24D9224-SPE2DB24FJGEK
    Delivery Order

The federal contract award is for the supply of pharmaceutical products, specifically the drug Xtandi 40 mg tablets, to the Defense Logistics Agency (DLA). The contract, valued at $4,169.59, is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. DMS Pharmaceutical Group is a key supplier of a wide range of pharmaceutical items, including branded, generic, and specialty medications, to support the recurring medical supply needs of military health facilities worldwide.

This award is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, valued at up to $499,999,999 and running through December 31, 2025. The IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to fulfill the diverse medical requirements of the Department of Defense (DoD) healthcare facilities. The contract has no set-aside designation, leveraging DMS Pharmaceutical Group's status as a woman-owned small business to secure direct awards for the federal government's pharmaceutical prime vendor programs supporting military medical facilities globally.

Generated 10/23/24, 9:04 AM